ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?

Keytruda’s first-in-class FDA approval as a first-line therapy in metastatic cervical cancer arrived in 2021 with a restriction. Now, researchers say new patient survival data suggest the Merck drug could be used in a broader patient population.